Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
Kodiak Sciences (KOD) reported a Q3 2026 loss of $1.05 per share, wider than expected. R&D expenses rose 15.5% YoY, while cash reserves decreased to $88.7M. The company raised $69M via stock sales. Positive phase III data for Zenkuda and abirafusp-ted were announced, with BLA submissions planned. KOD shares surged 287.1% YTD.
How this was made

The 30-second read
Why it matters
The earnings miss may trigger immediate sell pressure, but the successful trial data could attract biotech-focused investors and support the stock in the medium term.
Market read
KOD's earnings miss and trial success create a mixed short‑term outlook with potential longer‑term upside for biotech sector.
What to watch
Cash runway of $88.7M and upcoming AT‑M offering could dilute shares, affecting valuation.
Background
Kodiak Sciences reported Q3 2026 results with a wider loss than expected and disclosed positive Phase III trial outcomes for its lead candidates.
Ticker impact
Q3 2026 loss of $1.05 per share, wider than consensus, and positive Phase III trial data for Zenkuda and Abirafusp‑ted.
potential near‑term downside as earnings miss, but upside catalyst from Phase III data could limit decline.
Earnings miss drives sell‑off, but breakthrough trial outcomes provide a counterbalance and future upside.
Market effects
Positive late‑stage biotech data may lift peer biotech stocks despite earnings miss.
US biotech sector could see modest rally on trial news.
Limited to biotech investors; no broad market effect.
Counterpoint
Short sellers may overreact to the loss; trial data suggests a longer‑term upside.
Key entities
- companyKodiak Sciences Inc.
Biotech firm developing retinal disease therapies.
- companyRegeneron Pharmaceuticals
Comparator for trial data (Eylea).


